SidaSubSaharaV1, Ncbi, Merge, bibRecord, 002452

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Identifieur interne : 002452 ( Ncbi/Merge ); précédent : 002451; suivant : 002453

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Auteurs : Anushka Naidoo [Afrique du Sud] ; Kogieleum Naidoo ; Nonhlanhla Yende-Zuma ; Tanuja N. Gengiah ; Nesri Padayatchi ; Andrew L. Gray ; Sheila Bamber ; Gonasagrie Nair ; Salim S Abdool Karim

Source :

Antiviral therapy [ 2040-2058 ] ; 2014.

RBID : pubmed:24176943

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Agents antiVIH (effets indésirables), Agents antiVIH (usage thérapeutique), Antituberculeux (effets indésirables), Antituberculeux (usage thérapeutique), Facteurs de risque, Femelle, Humains, Incidence, Infections à VIH (), Infections à VIH (traitement médicamenteux), Mâle, Tuberculose (), Tuberculose (traitement médicamenteux).
MESH :
- effets indésirables : Agents antiVIH, Antituberculeux.
- traitement médicamenteux : Infections à VIH, Tuberculose.
- usage thérapeutique : Agents antiVIH, Antituberculeux.
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Humains, Incidence, Infections à VIH, Mâle, Tuberculose.

English descriptors

KwdEn :
- Adult, Anti-HIV Agents (adverse effects), Anti-HIV Agents (therapeutic use), Antitubercular Agents (adverse effects), Antitubercular Agents (therapeutic use), Female, HIV Infections (complications), HIV Infections (drug therapy), Humans, Incidence, Male, Middle Aged, Risk Factors, Tuberculosis (complications), Tuberculosis (drug therapy).
MESH :
- chemical , adverse effects : Anti-HIV Agents, Antitubercular Agents.
- chemical , therapeutic use : Anti-HIV Agents, Antitubercular Agents.
- complications : HIV Infections, Tuberculosis.
- drug therapy : HIV Infections, Tuberculosis.
- Adult, Female, Humans, Incidence, Male, Middle Aged, Risk Factors.

Abstract

Frequency of drug changes in combination antiretroviral therapy among patients starting both tuberculosis (TB) and HIV therapy, as a result of treatment-limiting toxicity or virological failure, is not well established.

DOI: 10.3851/IMP2701
PubMed: 24176943

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001648
to stream PubMed, to step Curation: 001648
to stream PubMed, to step Checkpoint: 001648

Links to Exploration step

pubmed:24176943

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.</title>
<author><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. naidooa2@ukzn.ac.za.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Naidoo, Kogieleum" sort="Naidoo, Kogieleum" uniqKey="Naidoo K" first="Kogieleum" last="Naidoo">Kogieleum Naidoo</name>
</author>
<author><name sortKey="Yende Zuma, Nonhlanhla" sort="Yende Zuma, Nonhlanhla" uniqKey="Yende Zuma N" first="Nonhlanhla" last="Yende-Zuma">Nonhlanhla Yende-Zuma</name>
</author>
<author><name sortKey="Gengiah, Tanuja N" sort="Gengiah, Tanuja N" uniqKey="Gengiah T" first="Tanuja N" last="Gengiah">Tanuja N. Gengiah</name>
</author>
<author><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name>
</author>
<author><name sortKey="Gray, Andrew L" sort="Gray, Andrew L" uniqKey="Gray A" first="Andrew L" last="Gray">Andrew L. Gray</name>
</author>
<author><name sortKey="Bamber, Sheila" sort="Bamber, Sheila" uniqKey="Bamber S" first="Sheila" last="Bamber">Sheila Bamber</name>
</author>
<author><name sortKey="Nair, Gonasagrie" sort="Nair, Gonasagrie" uniqKey="Nair G" first="Gonasagrie" last="Nair">Gonasagrie Nair</name>
</author>
<author><name sortKey="Karim, Salim S Abdool" sort="Karim, Salim S Abdool" uniqKey="Karim S" first="Salim S Abdool" last="Karim">Salim S Abdool Karim</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24176943</idno>
<idno type="pmid">24176943</idno>
<idno type="doi">10.3851/IMP2701</idno>
<idno type="wicri:Area/PubMed/Corpus">001648</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001648</idno>
<idno type="wicri:Area/PubMed/Curation">001648</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001648</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001648</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001648</idno>
<idno type="wicri:Area/Ncbi/Merge">002452</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.</title>
<author><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. naidooa2@ukzn.ac.za.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Naidoo, Kogieleum" sort="Naidoo, Kogieleum" uniqKey="Naidoo K" first="Kogieleum" last="Naidoo">Kogieleum Naidoo</name>
</author>
<author><name sortKey="Yende Zuma, Nonhlanhla" sort="Yende Zuma, Nonhlanhla" uniqKey="Yende Zuma N" first="Nonhlanhla" last="Yende-Zuma">Nonhlanhla Yende-Zuma</name>
</author>
<author><name sortKey="Gengiah, Tanuja N" sort="Gengiah, Tanuja N" uniqKey="Gengiah T" first="Tanuja N" last="Gengiah">Tanuja N. Gengiah</name>
</author>
<author><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name>
</author>
<author><name sortKey="Gray, Andrew L" sort="Gray, Andrew L" uniqKey="Gray A" first="Andrew L" last="Gray">Andrew L. Gray</name>
</author>
<author><name sortKey="Bamber, Sheila" sort="Bamber, Sheila" uniqKey="Bamber S" first="Sheila" last="Bamber">Sheila Bamber</name>
</author>
<author><name sortKey="Nair, Gonasagrie" sort="Nair, Gonasagrie" uniqKey="Nair G" first="Gonasagrie" last="Nair">Gonasagrie Nair</name>
</author>
<author><name sortKey="Karim, Salim S Abdool" sort="Karim, Salim S Abdool" uniqKey="Karim S" first="Salim S Abdool" last="Karim">Salim S Abdool Karim</name>
</author>
</analytic>
<series><title level="j">Antiviral therapy</title>
<idno type="eISSN">2040-2058</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Anti-HIV Agents (adverse effects)</term>
<term>Anti-HIV Agents (therapeutic use)</term>
<term>Antitubercular Agents (adverse effects)</term>
<term>Antitubercular Agents (therapeutic use)</term>
<term>Female</term>
<term>HIV Infections (complications)</term>
<term>HIV Infections (drug therapy)</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Risk Factors</term>
<term>Tuberculosis (complications)</term>
<term>Tuberculosis (drug therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Agents antiVIH (effets indésirables)</term>
<term>Agents antiVIH (usage thérapeutique)</term>
<term>Antituberculeux (effets indésirables)</term>
<term>Antituberculeux (usage thérapeutique)</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Infections à VIH ()</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Tuberculose ()</term>
<term>Tuberculose (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Antitubercular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Antitubercular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term>
<term>Antituberculeux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
<term>Tuberculose</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term>
<term>Antituberculeux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Infections à VIH</term>
<term>Mâle</term>
<term>Tuberculose</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Frequency of drug changes in combination antiretroviral therapy among patients starting both tuberculosis (TB) and HIV therapy, as a result of treatment-limiting toxicity or virological failure, is not well established.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24176943</PMID>
<DateCreated><Year>2014</Year>
<Month>04</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>12</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2040-2058</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>2</Issue>
<PubDate><Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Antiviral therapy</Title>
<ISOAbbreviation>Antivir. Ther. (Lond.)</ISOAbbreviation>
</Journal>
<ArticleTitle>Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.</ArticleTitle>
<Pagination><MedlinePgn>161-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3851/IMP2701</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frequency of drug changes in combination antiretroviral therapy among patients starting both tuberculosis (TB) and HIV therapy, as a result of treatment-limiting toxicity or virological failure, is not well established.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Patients in the Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT) trial were randomized to initiate antiretroviral therapy (ART) either early or late during TB treatment or after completion of TB treatment. Drug changes due to toxicity (defined as due to grade 3 or 4 adverse events) or virological failure (defined as viral load >1,000 copies/ml on two occasions, taken ≥4 weeks apart) were assessed in these patients.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 501 TB-HIV-coinfected patients were followed for a mean of 16.0 months (95% CI 15.5, 16.6) after ART initiation. The standard first-line antiretrovirals used were efavirenz, lamivudine and didanosine. Individual drug switches for toxicity occurred in 14 patients (incidence rate 2.1 per 100 person-years, 95% CI 1.1, 3.5), and complete regimen changes due to virological failure in 25 patients (incidence rate 3.7 per 100 person-years, 95% CI 2.4, 5.5). The most common treatment limiting toxicities were neuropsychiatric effects (n=4, 0.8%), elevated transaminase levels and hyperlactataemia (n=3, 0.6%), and peripheral neuropathy (n=2, 0.4%). Complete regimen change due to treatment failure was more common in patients with CD4(+) T-cell count <50 cells/mm(3) (P<0.001) at ART initiation and body mass index >25 kg/m(2) (P=0.01) at entry into the study.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both drug switches and complete regimen change were uncommon in patients cotreated for TB-HIV with the chosen regimen. Patients with severe immunosuppression need to be monitored carefully, as they were most at risk for treatment failure requiring regimen change.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naidoo</LastName>
<ForeName>Anushka</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. naidooa2@ukzn.ac.za.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Naidoo</LastName>
<ForeName>Kogieleum</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yende-Zuma</LastName>
<ForeName>Nonhlanhla</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gengiah</LastName>
<ForeName>Tanuja N</ForeName>
<Initials>TN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Padayatchi</LastName>
<ForeName>Nesri</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gray</LastName>
<ForeName>Andrew L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bamber</LastName>
<ForeName>Sheila</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nair</LastName>
<ForeName>Gonasagrie</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Karim</LastName>
<ForeName>Salim S Abdool</ForeName>
<Initials>SS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>D43 TW000231</GrantID>
<Acronym>TW</Acronym>
<Agency>FIC NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U19 AI051794</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI51794</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>D43TW00231</GrantID>
<Acronym>TW</Acronym>
<Agency>FIC NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>10</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Antivir Ther</MedlineTA>
<NlmUniqueID>9815705</NlmUniqueID>
<ISSNLinking>1359-6535</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2006;6:21</RefSource>
<PMID Version="1">16445860</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Clin Pharmacol. 2012 May;68(5):689-95</RefSource>
<PMID Version="1">22108776</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Jan 4;16(1):75-83</RefSource>
<PMID Version="1">11741165</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):428-37</RefSource>
<PMID Version="1">22433846</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2003 Oct 17;17(15):2191-9</RefSource>
<PMID Version="1">14523276</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):433-42</RefSource>
<PMID Version="1">17786128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Oct 20;365(16):1492-501</RefSource>
<PMID Version="1">22010915</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS Res Ther. 2011 Nov 07;8(1):42</RefSource>
<PMID Version="1">22060823</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Jun 1;48(11):1617-23</RefSource>
<PMID Version="1">19385733</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 2007 Nov;38(6):1053-60</RefSource>
<PMID Version="1">18613546</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Saf. 2011 Jul;10(4):559-74</RefSource>
<PMID Version="1">21204737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Jun 15;48(12):1760-2</RefSource>
<PMID Version="1">19438396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hepatology. 2002 Jan;35(1):182-9</RefSource>
<PMID Version="1">11786975</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2000 Jan 5;283(1):74-80</RefSource>
<PMID Version="1">10632283</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Mar 11;367(9513):817-24</RefSource>
<PMID Version="1">16530575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2006 Jan 2;20(1):131-2</RefSource>
<PMID Version="1">16327334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2004 Apr 17;363(9417):1253-63</RefSource>
<PMID Version="1">15094269</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):631-3</RefSource>
<PMID Version="1">18665026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2002 Jul 1;186(1):23-31</RefSource>
<PMID Version="1">12089658</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Infect Dis. 2009;9:81</RefSource>
<PMID Version="1">19493344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2002 Mar 29;16(5):737-45</RefSource>
<PMID Version="1">11964530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2007 Dec;11(12):1282-9</RefSource>
<PMID Version="1">18229435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Mar 25;19(5):463-71</RefSource>
<PMID Version="1">15764851</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Gastroenterol Hepatol. 2005 May;3(5):482-8</RefSource>
<PMID Version="1">15880318</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jun 19;21(10):1301-8</RefSource>
<PMID Version="1">17545706</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Thorax. 2004 Aug;59(8):704-7</RefSource>
<PMID Version="1">15282393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>East Afr Med J. 2000 Jan;77(1):13-5</RefSource>
<PMID Version="1">10944831</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J STD AIDS. 2009 May;20(5):339-45</RefSource>
<PMID Version="1">19386972</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Feb 25;362(8):697-706</RefSource>
<PMID Version="1">20181971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2010 Mar;10(3):155-66</RefSource>
<PMID Version="1">20185094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Oct 20;365(16):1471-81</RefSource>
<PMID Version="1">22010913</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Oct 20;365(16):1482-91</RefSource>
<PMID Version="1">22010914</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>AIDS. 2000 Dec 22;14(18):2895-902</RefSource>
<PMID Version="1">11153671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2006 Jan;6(1):53-9</RefSource>
<PMID Version="1">16377535</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2010 Mar 1;50(5):779-86</RefSource>
<PMID Version="1">20121574</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS539605</OtherID>
<OtherID Source="NLM">PMC3984627</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>09</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>11</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>11</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24176943</ArticleId>
<ArticleId IdType="doi">10.3851/IMP2701</ArticleId>
<ArticleId IdType="pmc">PMC3984627</ArticleId>
<ArticleId IdType="mid">NIHMS539605</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Afrique du Sud</li>
</country>
</list>
<tree><noCountry><name sortKey="Bamber, Sheila" sort="Bamber, Sheila" uniqKey="Bamber S" first="Sheila" last="Bamber">Sheila Bamber</name>
<name sortKey="Gengiah, Tanuja N" sort="Gengiah, Tanuja N" uniqKey="Gengiah T" first="Tanuja N" last="Gengiah">Tanuja N. Gengiah</name>
<name sortKey="Gray, Andrew L" sort="Gray, Andrew L" uniqKey="Gray A" first="Andrew L" last="Gray">Andrew L. Gray</name>
<name sortKey="Karim, Salim S Abdool" sort="Karim, Salim S Abdool" uniqKey="Karim S" first="Salim S Abdool" last="Karim">Salim S Abdool Karim</name>
<name sortKey="Naidoo, Kogieleum" sort="Naidoo, Kogieleum" uniqKey="Naidoo K" first="Kogieleum" last="Naidoo">Kogieleum Naidoo</name>
<name sortKey="Nair, Gonasagrie" sort="Nair, Gonasagrie" uniqKey="Nair G" first="Gonasagrie" last="Nair">Gonasagrie Nair</name>
<name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name>
<name sortKey="Yende Zuma, Nonhlanhla" sort="Yende Zuma, Nonhlanhla" uniqKey="Yende Zuma N" first="Nonhlanhla" last="Yende-Zuma">Nonhlanhla Yende-Zuma</name>
</noCountry>
<country name="Afrique du Sud"><noRegion><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002452 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002452 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:24176943
   |texte=   Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:24176943" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaSubSaharaV1

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024

	Le SIDA en Afrique subsaharienne (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA en Afrique subsaharienne (serveur d'exploration)

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki